Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a ...

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a higher risk for infection than nonoverlapping switches of biologics.

Vedolizumab as a first-line biologic in UC offers cost savings and clinical benefits, improving QALYs compared to TNF-α inhibitors. In CD, vedolizumab provides incremental benefits but incurs ...